WEST HARRISON, NY, United States, via ETELIGIS INC., 06/29/2015 – – CEL-SCI Corporation, (NYSE MKT: CVM), arguably the most undervalued Phase III biotech company, is featured in the June 25 issue of Flaherty Special Situation Newsletter #38 Update. Over the next 10 to 12 months three events could have a significant impact on CEL-SCI’s share price. The first would be full enrollment of cancer patients in their ongoing global Multikine regimen Phase III trial. The goal is to achieve that by March 31, 2016. Next would be developing another application for Multikine such as treating health problems caused by viruses like Human Papilloma Virus in HIV infected patients. The third would be a conclusion to CEL-SCI’s $50 million law suit against CEL-SCI’s former clinical research organization for breach of contract and fraud with a judgment potentially including extra sizable millions in consequential damages.
This turnaround aims to enroll 880 head and neck cancer patients in over 100 sites in approximately 25 countries. Success in this global Phase III trial of its lead immunotherapy drug regime Multikine could be rewarded with a one day stock jump of billions. More importantly, Multikine could have the potential to become the fourth standard of care for cancer, joining surgery, chemo and radiation. Other tantalizing possibilities exist, for example, a vaccine for rheumatoid arthritis. Dreamer CEO Geert Kersten and his outstanding team are building a keeper.
Our complete in depth sponsored CEL-SCI Corporation Buy report can be found archived on our Flaherty Financial News website at http://www.flahertyfinancialnews.com/ .
Direct Server Link to The Report – With The Modern Social Share Buttons:
About Flaherty Financial News Inc.
Flaherty Financial News Inc. ("FFN") is the publisher of totally-electronic coverage of interesting public companies. FFN was launched in 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., and his son Brian, President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years and also Editor-in-Chief of Equities Special Situations, Bob had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest. He is also an award-winning retired Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all-time Forbes record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School. A former president of the New York Financial Writers’ Association, Bob is a co-founder of their annual student scholarship program and their annual award for significant long-term achievement in financial journalism.
About CEL-SCI Corporation.
CEL-SCI’s work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy Multikine (Leukocyte Interleukin, injection) is currently being studied in a pivotal Phase III clinical trial as a potential neo-adjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care as compared to subjects treated with the current standard of care only is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multkine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Naval Medical Center, San Diego, under a CRADA (Cooperative Research and Development Agreement).
CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. The Company has operations in Vienna, Virginia and in and near Baltimore, Maryland.
This news release contains “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of l995) regarding the special situation report on CEL-SCI Corporation and its future business plans. These statements involve known and unknown risks and uncertainties, which may cause actual results and future achievements to be materially different than those implied by these forward-looking statements. Flaherty Financial News Inc. and CEL-SCI Corporation have and undertake no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in their expectations of future events. Our full disclaimer and safe harbor statement appears in our special situation newsletter.
Flaherty Financial News Inc.
Robert J. Flaherty, Editor and Chairman
Phone: (914) 831-1151
SOURCE: Flaherty Financial News Inc.